Drugs in Pregnancy and Lactation, 11th ed. G.G. Briggs, R.K. Freeman, C.V. Towers, A.B. Forinash
Micromedex (www.micromedexsolutions.com)
Answers to questions patients ask
1 Q1. Can I continue taking my herbal supplements while having IVF?A1. Women and their partners are encouraged to discontinue herbal supplements while undergoing assisted conception. This stems from a lack of good‐quality data on the efficacy and safety of herbal products. Furthermore, it is possible that unlicensed drugs may negatively impact upon patients’ perioperative care and treatment outcomes.
2 Q2 I take medication for a chronic illness. How will this affect my IVF cycle?A2. Women on chronic medication should undergo a risk assessment, usually performed by their general practitioner, to ascertain whether a referral to a preconception specialist clinic is warranted. Although patients will usually be able to continue their medications or switch to pregnancy‐friendly alternatives, specialist input may be required to counsel the woman about the potential effect of pregnancy on her condition, and vice versa.
3 Q3 Is it best to not take any drugs in pregnancy?A3. Whenever possible, the need to continue drugs in pregnancy should be assessed at regular intervals by all clinicians involved in a woman’s care. In addition, women with complex comorbidities (e.g. inflammatory bowel disease, asthma, renal disease, organ transplants) should be followed‐up in a tertiary referral hospital with multidisciplinary links, so that treatment can be optimized with minimal disruption to fetal development and growth.
References
1 1 Wilson JG, Warkany, J. The history of organized teratology in North America. Teratology. 1985; 31(2):285–96.
2 2 Fraser FC. Drug‐induced teratogenesis. Can Med Assoc J. 1962; 87:683–4.
3 3 Hale F. Pigs born without eye balls. Journal of Heredity. 1933; 24(3):105–106.
4 4 Lenz W, Knapp. K. Thalidomide embryopathy. Arch Environ Health. 1962; 5:100–5.
5 5 Lowe S. Prescribing in pregnancy. Obstet Med. 2016; 9(1):3.
6 6 Hardy JR et al. Safety of medications prescribed before and during early pregnancy in a cohort of 81,975 mothers from the UK General Practice Research Database. Pharmacoepidemiol Drug Saf. 2006; 15(8):555–64.
7 7 Gagne JJ et al. Prescription drug use during pregnancy: a population‐based study in Regione Emilia‐Romagna, Italy. Eur J Clin Pharmacol. 2008; 64(11):1125–32.
8 8 Engeland A et al. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiol Drug Saf. 2018; 27(9):995–1004.
9 9 Irvine L et al. Drugs dispensed in primary care during pregnancy: a record‐linkage analysis in Tayside, Scotland. Drug Saf. 2010; 33(7):593–604.
10 10 van Gelder MM et al. Drugs associated with teratogenic mechanisms. Part I: dispensing rates among pregnant women in the Netherlands, 1998–2009. Hum Reprod. 2014; 29(1):161–7.
11 11 Mitchell AA et al. Medication use during pregnancy, with particular focus on prescription drugs:1976–2008. American Journal of Obstetrics and Gynecology. 2011;205(1):51.e1–51.e518.
12 12 Tinker SC et al. Challenges in studying modifiable risk factors for birth defects. Curr Epidemiol Rep. 2015; 2(1):23–30.
13 13 Dillon P et al. Prevalence of prescribing in pregnancy using the Irish primary care research network: a pilot study. BMC Pregnancy Childbirth. 2015; 15:67.
14 14 Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011; 157C(3):175–82.
15 15 Daw JR et al. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2011; 20(9):895–902.
16 16 Demailly R et al. Prescription drug use during pregnancy in France: a study from the national health insurance permanent sample. Pharmacoepidemiol Drug Saf. 2017; 26(9):1126–1134.
17 17 McCormack SA, Best BM. Obstetric pharmacokinetic dosing studies are urgently needed. Front Pediatr. 2014; 2:9.
18 18 van der Graaf R et al. Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach. Trials. 2018; 19(1):78.
19 19 HHS, FDA. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist. 2014; 79(233):72063–103.
20 20 Pernia S, GDeMaagd G. The new pregnancy and lactation labeling rule. PT. 2016; 41(11):713–5.
21 21 British National Formulary, Number 78 (BNF 78), September 2019–March 2020. 2019.
22 22 Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1. Teratology. Obstet Gynecol. 2009; 113(1):166–88.
23 23 Cragan JD et al. Ensuring the safe and effective use of medications during pregnancy: planning and prevention through preconception care. Matern Child Health J. 2006; 10(5 Suppl):S129–35.
24 24 Nelson‐Piercy C. Handbook of obstetric medicine. Boca Raton, FL: CRC Press.
25 25 Henderson E, Mackillop L. Prescribing in pregnancy and during breast feeding: using principles in clinical practice. Postgrad Med J. 2011; 87(1027):349–54.
26 26 Bramham K et al. Chronic hypertension and pregnancy outcomes: systematic review and meta‐analysis. BMJ. 2014;348: g2301.
27 27 Mills JL. Malformations in infants of diabetic mothers. Birth Defects Res A Clin Mol Teratol. 2010; 88(10):769–78.
28 28 Tomson T, Xue H, Battino D. Major congenital malformations in children of women with epilepsy. Seizure. 2015; 28:46–50.
29 29 Genuis SJ, Genuis RA. Preconception care: a new standard of care within maternal health services. Biomed Res Int. 2016; 2016:6150976.
30 30 Lassi ZS et al. Preconception care: screening and management of chronic disease and promoting psychological health. Reprod Health. 2014; 11 Suppl 3:S5.
31 31 Ethics Committee of the American Society for Reproductive Medicine. Electronic address, A.A.O. and M. Ethics Committee of the American Society for Reproductive, Provision of fertility services for women at increased risk of complications during fertility treatment or pregnancy: an Ethics Committee opinion. Fertil Steril. 2016; 106(6):1319–23.
32 32 Bisson DL et al. Antenatal and postnatal analgesia: scientific impact paper no. 59. BJOG. 2019; 126(4):e114–24.
33 33 Soh MC, MacKillop L. Biologics in pregnancy–for the obstetrician. Obstet Gynaecol. 2016; 18(1):25–32.
34 34 Usadi RS, Merriam KS. On‐label and off‐label drug use in the treatment of female infertility. Fertil Steril. 2015; 103(3):583–94.
35 35 Wise J. Show patients evidence for treatment “add‐ons,” fertility clinics are told. BMJ. 2019;364: l226.
36 36 Zhang T, et al. Successful treatment with intrauterine delivery of dexamethasone for repeated implantation failure. Am J Reprod Immunol. 2017; 78(6).
37 37 Salek FS, Bigos KL, Kroboth PD. The influence of hormones and pharmaceutical agents on DHEA and DHEA‐S concentrations: a review of clinical studies. J Clin Pharmacol. 2002; 42(3):247–66.
38 38 Martini AE, et al. Evaluating the utility of intralipid infusion to improve live birth rates in patients with recurrent pregnancy loss or recurrent implantation failure. J Hum Reprod Sci. 2018; 11(3):261–268.
39 39 Tilburt JC, Kaptchuk TJ. Herbal medicine research and global health: an ethical analysis. Bull World Health Organ. 2008; 86(8):594–9.
40 40 Smith JF, et al. The use of complementary and alternative fertility treatment in couples seeking fertility care: data from a prospective cohort in